{
    "root": "0a77dd1f-510b-41f4-9b10-bbd179528188",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Metformin Hydrochloride",
    "value": "20250226",
    "ingredients": [
        {
            "name": "METFORMIN HYDROCHLORIDE",
            "code": "786Z46389E"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "POVIDONE K90",
            "code": "RDH86HJV5Z"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "BLACKBERRY",
            "code": "8A6OMU3I8L"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "metformin hydrochloride tablets indicated adjunct diet exercise improve glycemic control adults pediatric patients 10 years age older type 2 diabetes mellitus .",
    "contraindications": "adult metformin hydrochloride tablets : \u2022 starting dose : 500 mg orally twice day 850 mg day , meals ( 2.1 ) \u2022 increase dose increments 500 mg weekly 850 mg every 2 weeks , maximum dose 2550 mg per day , given divided doses ( 2.1 ) \u2022 doses 2000 mg may better tolerated given 3 times day meals ( 2.1 ) pediatric metformin hydrochloride tablets : \u2022 starting dose : 500 mg orally twice day , meals ( 2.2 ) \u2022 increase increments 500 mg weekly maximum 2000 mg per day , given divided doses twice daily ( 2.2 ) renal impairment : \u2022 prior initiation , assess renal function estimated glomerular filtration rate ( egfr ) ( 2.3 ) \u2022 patients egfr 30 ml/minute/1.73 2 ( 2.3 ) \u2022 initiation recommended patients egfr 30 45 ml/minute/1.73 2 ( 2.3 ) \u2022 assess risk/benefit continuing egfr falls 45 ml/minute/1.73 2 ( 2.3 ) \u2022 discontinue egfr falls 30 ml/minute/1.73 2 ( 2.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "metformin hydrochloride tablets contraindicated patients : \u2022severe renal impairment ( egfr 30 ml/min/1.73 2 ) [ ( 5.1 ) ] . \u2022hypersensitivity metformin . \u2022acute chronic metabolic acidosis , including diabetic ketoacidosis , without coma .",
    "indications_original": "Metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.",
    "contraindications_original": "Adult Dosage for metformin hydrochloride tablets: \u2022 Starting dose: 500 mg orally twice a day or 850 mg once a day, with meals ( 2.1 ) \u2022 Increase the dose in increments of 500 mg weekly or 850 mg every 2 weeks, up to a maximum dose of 2550 mg per day, given in divided doses ( 2.1 ) \u2022 Doses above 2000 mg may be better tolerated given 3 times a day with meals ( 2.1 ) Pediatric Dosage for metformin hydrochloride tablets: \u2022 Starting dose: 500 mg orally twice a day, with meals ( 2.2 ) \u2022 Increase dosage in increments of 500 mg weekly up to a maximum of 2000 mg per day, given in divided doses twice daily ( 2.2 ) Renal Impairment: \u2022 Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) ( 2.3 ) \u2022 Do not use in patients with eGFR below 30 mL/minute/1.73 m 2 ( 2.3 ) \u2022 Initiation is not recommended in patients with eGFR between 30 to 45 mL/minute/1.73 m 2 ( 2.3 ) \u2022 Assess risk/benefit of continuing if eGFR falls below 45 mL/minute/1.73 m 2 ( 2.3 ) \u2022 Discontinue if eGFR falls below 30 mL/minute/1.73 m 2 ( 2.3 )",
    "adverseReactions_original": "Metformin hydrochloride tablets are contraindicated in patients with:\n                  \n                     \n                        \u2022Severe renal impairment (eGFR below 30 mL/min/1.73 m    2) [    \n                           see Warnings and Precautions (5.1)\n                        ].   \n                     \n                        \u2022Hypersensitivity to metformin.\n                     \n                        \u2022Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma."
}